Genedx reaffirms 2026 revenue guidance of $475M-$490M while expecting meaningful collection-rate uplift starting in Q4 (NASDAQ:WGS)
· seekingalpha.com
GeneDx (WGS) Q2 2026 earnings call recap: record exome/genome growth, return to profitability, Carelon coverage shift, and Q4–2027 outlook—Read now.
To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
If you have an ad-blocker enabled you may be blocked from ...